SCHEMBL22304539

SCHEMBL22304539

C[C@@H]1CN(CC(C)(C)C)C[C@H](C)O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.45
EBP Q15125 2/20 0.45
PDK1 Q15118 1/20 0.39
KDM4E B2RXH2 3/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ADORA3 P0DMS8 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD3 P35462 1/20 0.36
KCNH2 Q12809 1/20 0.36
NR3C1 P04150 2/20 0.36
NR3C2 P08235 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP2A13 Q16696 1/20 0.36
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12665784 1.00 SIGMAR1 (0.45) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL17886531 0.77 SIGMAR1 (0.52) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL17886534 0.77 SIGMAR1 (0.52) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL12444032 0.77 SIGMAR1 (0.52) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL22307606 0.77 GBA1 (0.33)
SCHEMBL10159852 0.77 KDM4E (0.34) KDM4E
SCHEMBL15541193 0.77 SIGMAR1 (0.40) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL23542974 0.76 SIGMAR1 (0.42) SIGMAR1EBPPDK1KDM4EHTT
SCHEMBL17540128 0.74
SCHEMBL22304938 0.74 PDK1 (0.42) PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247800-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS NOX1, CYBB, NOX4 SIGMAR1 3131/4885EBP 1343/4885PDK1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.